Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04074616 · ClinicalTrials.gov registry record · NA
Reducing Anticholinergic Bladder Medication Use in Spinal Cord Injury With Home Neuromodulation
A NA study of Neurogenic Bladder and Chronic Spinal Cord Injury, sponsored by The University of Texas Health Science Center, Houston.
- Completed
- Registry status
- NA
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT04074616: Completed NA study of Neurogenic Bladder and Chronic Spinal Cord Injury, sponsored by The University of Texas Health Science Center, Houston.
NCT04074616 is a NA study of Neurogenic Bladder and Chronic Spinal Cord Injury that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 50 participants, below the 90-participant average among 16 other Neurogenic Bladder trials with a reported enrollment target (44% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04074616, a NA study of Neurogenic Bladder and Chronic Spinal Cord Injury, has completed, sponsored by The University of Texas Health Science Center, Houston.
- COMPLETED
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the efficacy of home transcutaneous tibial nerve stimulation (TTNS) in spinal cord injury(SCI) and to determine the impact on quality of life using TTNS at home
Conditions Studied
Interventions
- DEVICE High Dose
- DEVICE Low dose
Study Locations (1)
Texas
- The University of Texas Health Science Center at Houston - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2019-11-19 |
| Est. Completion | 2023-04-20 |
| Phase | NA |
What the finished NCT04074616 record still lists
NCT04074616 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 90-participant average among 16 other Neurogenic Bladder trials with a reported enrollment target (44% lower).
The record links to 2 conditions, with Neurogenic Bladder appearing as the primary indexed condition, and to 2 interventions - of which High Dose is the first listed.
NCT04074616 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT04074616 about?
NCT04074616 is a clinical study titled "Reducing Anticholinergic Bladder Medication Use in Spinal Cord Injury With Home Neuromodulation". The purpose of this study is to determine the efficacy of home transcutaneous tibial nerve stimulation (TTNS) in spinal cord injury(SCI) and to determine the impact on quality of life using TTNS at home
What is the current status of trial NCT04074616?
This trial is currently completed. It is a NA study. The enrollment target is 50 participants. The study started on 2019-11-19. Estimated completion is 2023-04-20.
What conditions does trial NCT04074616 study?
This clinical trial studies the following conditions: Neurogenic Bladder, Chronic Spinal Cord Injury.
What interventions are being tested in trial NCT04074616?
The interventions under investigation include: High Dose (DEVICE), Low dose (DEVICE).
Who is sponsoring clinical trial NCT04074616?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04074616 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neurogenic Bladder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04074616's enrollment target sits among peer trials
50 9th of 16 higher than 8 of 16 other Neurogenic Bladder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neurogenic Bladder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Neuromodulating Cortical Regions Involved in Neurogenic Bladder in MS
RECRUITING · NA
-
Vascularized Composite Bladder Allograft Transplantation
RECRUITING · NA
-
Effect of Chlorhexidine Gluconate Bladder Instillations in Patients With Chronic Suprapubic Catheters on Unplanned Healthcare Encounters and Quality of Life
RECRUITING · NA
-
Electrical Stimulation for Continence After Spinal Cord Injury
ACTIVE NOT RECRUITING · NA
-
Spinal COrd NeuromodulaTor by SpIneX and ScoNE to Treat NeurogeniC BladdEr - SCONE "CONTINENCE" Clinical Study
COMPLETED · NA
-
Intravesical Lactobacillus Crispatus: Clinical Safety and Microbiome Evaluation
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI